Today, iThera Medical announces the installation of the world’s first RSOM Explorer ms-P50, at the CRUK Cambridge Institute. Adding to the extensive array of imaging tools used at the institute, this system will help researchers better understand the processes involved in tumor growth and therapy response. By means of the photoacoustic effect, this system can create 3D maps of the tumor areas based on hemoglobin or melanin contrast. Researchers can use oxygen saturation maps to derive information about the behavior of blood vessels that allow the tumor to grow, or how they are responding to therapy.
Dr Sarah Bohndiek, group leader at the CRUK CI and head of the ‘Vision Lab’ said: “Combining exquisite resolution with the ability to resolve tumor hemoglobin concentration and oxygenation status, the RSOM Explorer ms-P50 will be an excellent addition to our research imaging portfolio. In particular, we are excited to use this new capability to study the heterogeneity of the delivery of oxygen and nutrients in cancer during chemo- and radiotherapy, and also to link our findings with future clinical studies.”
“We are thrilled to extend our collaboration with the ‘Vision Lab’ at Cambridge”, says Christian Wiest, co-founder and CEO of iThera Medical. “For the last few years, we have successfully worked on various joint studies using our macroscopic preclinical and clinical imaging systems. Now we can leverage this partnership to establish our mesoscopic multispectral RSOM imaging technology in the field of cancer research.”
The Cancer Research UK Cambridge Institute combines basic and clinical research with innovative technologies to address critical questions in the prevention, diagnosis and treatment of cancer. As one of the largest cancer research facilities in Europe, the Institute provides an unrivalled biomedical research environment, bringing together the world-class science of the University of Cambridge with clinical and industrial partners at the Cambridge Biomedical Campus.
For further information, please contact:
Phone: +49 (0) 89 700 7449-21